Harrow Health, Inc. (HROW)
Price:
38.23 USD
( - -0.09 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Viatris Inc.
VALUE SCORE:
6
2nd position
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
The best
Lantheus Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-17 12:06:00NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
prnewswire.com
2025-08-16 10:00:00NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock
zacks.com
2025-08-15 13:21:06Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stock to Buy for August 15th
zacks.com
2025-08-15 11:01:09ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet
zacks.com
2025-08-15 10:55:21The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Harrow's Ambitious Guidance Puts It In The Proving Ground
seekingalpha.com
2025-08-14 23:09:36Harrow's Q2 results were solid, but meeting ambitious full-year revenue guidance will require flawless execution amid recent topline misses and a challenging market. VEVYE, IHEEZO, and TRIESENCE are key growth drivers, but VEVYE's revenue must accelerate and biosimilars add complexity and legal risk to the thesis. Aggressive acquisitions have left Harrow with high debt and limited cash, making continued operational execution critical to avoid financial strain.
Harrow: Exciting Times In Store
seekingalpha.com
2025-08-13 17:39:42We are reiterating a Buy call on Harrow, Inc. for investment, not just trading, due to strong sales growth, product launches, and market share gains. Q2 showed 30% revenue growth and a dramatic earnings beat, with margins rebounding and profitability achieved; the outlook remains bullish despite a revenue miss. VEVYE and IHEEZO are driving prescription and revenue growth, with management guiding for $100M+ VEVYE revenue and record IHEEZO sales in 2025.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-13 12:05:00NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-12 14:47:49Harrow, Inc. (NASDAQ:HROW ) Q2 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants Andrew R. Boll - CFO & Corporate Secretary Mark L.
Harrow Announces Second-Quarter 2025 Financial Results
globenewswire.com
2025-08-11 16:01:00Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
prnewswire.com
2025-08-11 10:00:00NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-09 12:29:00NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
prnewswire.com
2025-08-06 10:00:00NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
globenewswire.com
2025-08-06 07:00:00NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright's 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com
2025-08-04 11:00:21Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-01 10:00:00NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
No data to display
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-17 12:06:00NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
prnewswire.com
2025-08-16 10:00:00NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock
zacks.com
2025-08-15 13:21:06Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stock to Buy for August 15th
zacks.com
2025-08-15 11:01:09ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet
zacks.com
2025-08-15 10:55:21The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Harrow's Ambitious Guidance Puts It In The Proving Ground
seekingalpha.com
2025-08-14 23:09:36Harrow's Q2 results were solid, but meeting ambitious full-year revenue guidance will require flawless execution amid recent topline misses and a challenging market. VEVYE, IHEEZO, and TRIESENCE are key growth drivers, but VEVYE's revenue must accelerate and biosimilars add complexity and legal risk to the thesis. Aggressive acquisitions have left Harrow with high debt and limited cash, making continued operational execution critical to avoid financial strain.
Harrow: Exciting Times In Store
seekingalpha.com
2025-08-13 17:39:42We are reiterating a Buy call on Harrow, Inc. for investment, not just trading, due to strong sales growth, product launches, and market share gains. Q2 showed 30% revenue growth and a dramatic earnings beat, with margins rebounding and profitability achieved; the outlook remains bullish despite a revenue miss. VEVYE and IHEEZO are driving prescription and revenue growth, with management guiding for $100M+ VEVYE revenue and record IHEEZO sales in 2025.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-13 12:05:00NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-12 14:47:49Harrow, Inc. (NASDAQ:HROW ) Q2 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants Andrew R. Boll - CFO & Corporate Secretary Mark L.
Harrow Announces Second-Quarter 2025 Financial Results
globenewswire.com
2025-08-11 16:01:00Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
prnewswire.com
2025-08-11 10:00:00NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-09 12:29:00NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
prnewswire.com
2025-08-06 10:00:00NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
globenewswire.com
2025-08-06 07:00:00NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright's 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com
2025-08-04 11:00:21Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
globenewswire.com
2025-08-01 10:00:00NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.